7.5. intravesical chemoablation neoadjuvant treatment. two different modalities administering chemotherapy first-line approach presumed nmibc reported: neoadjuvant intravesical chemotherapy turb chemoresection tumour replacement turb. neoadjuvant hypothesis-generating findings older rct comparing immediate pre-operative device-assisted (emda) mmc post-operative si mmc turb only, showed improved long-term rfs among patients treated prior turb , thus even suggest long-term effect neoadjuvant instillations. reproduced groups, two recent small neoadjuvant rcts reported conflicting results ability neoadjuvant administration mmc improve outcomes standard approach . chemoablation older marker lesion studies shown chemoablation single intravesical chemotherapy instillation achieve complete response proportion patients ; therefore, making possible avoid turb. recurrent low-grade recurrent ta tumours , 4 6 intravesical mmc instillations achieved complete response 37% 57% patients, respectively. update dablaca-13 rct evaluating chemoablation 40 mg/40 ml intravesical mmc three times week 2 weeks without preceding biopsy standard turb, 12-month rfs 36% chemoablation group vs. 43% turb group, statistical significant difference . despite lack long-term outcomes, chemoablation appears promising treatment option well-selected nmibc patients potentially help avoid unnecessary turb, specifically elderly patients intermediate-risk nmibc .